Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan.
Ann Surg Oncol. 2017 Sep;24(9):2752-2761. doi: 10.1245/s10434-017-5972-6. Epub 2017 Jul 6.
It remains controversial whether the degree of venous involvement really is associated with borderline resectability of pancreatic cancer.
A single-center retrospective review of patients who underwent upfront pancreaticoduodenectomy for T3 pancreatic cancer without arterial involvement was performed. The patients were classified as having resectable tumors without venous contact (R group), resectable tumors with venous contact of 180° or less (R-PV group), and borderline resectable tumors with venous contact greater than 180° (BR-PV group). The unresectable group included those who had unresected tumors with paraaortic lymph node metastasis, positive peritoneal lavage cytology, or locally advanced disease. The overall survival and prognostic factors were analyzed.
The study enrolled 299 resected patients, including 141 patients in the R group, 119 patients in the R-PV group, and 39 patients in the BR-PV group. The overall survival did not differ significantly between the R-PV group and the BR-PV group (median survival, 20.7 vs 18.6 months; P = 0.807). Among the 158 patients who had tumors with venous contact, only a tumor size of 50 mm or larger (P = 0.041) was an independent prognostic factor in a multivariate analysis, and the overall survival for the patients with both venous contact and tumor size 50 mm or larger was comparable with that for the unresectable group (P = 0.547).
The degree of venous involvement may not be associated with the resectability of pancreatic head cancer, whereas tumors 50 mm in size or larger that develop venous invasion may be categorized as borderline resectable pancreatic cancers.
静脉受累程度是否与胰腺癌的边界可切除性真正相关仍存在争议。
对未发生动脉受累的 T3 期胰腺癌行直接胰十二指肠切除术的患者进行单中心回顾性研究。患者分为无静脉接触的可切除肿瘤(R 组)、静脉接触小于或等于 180°的可切除肿瘤(R-PV 组)和静脉接触大于 180°的边界可切除肿瘤(BR-PV 组)。不可切除组包括主动脉旁淋巴结转移、腹腔灌洗液细胞学阳性或局部晚期疾病的未切除肿瘤患者。分析总生存率和预后因素。
研究纳入 299 例可切除患者,其中 R 组 141 例,R-PV 组 119 例,BR-PV 组 39 例。R-PV 组和 BR-PV 组的总生存率无显著差异(中位生存时间,20.7 个月 vs 18.6 个月;P=0.807)。在 158 例有静脉接触的肿瘤患者中,仅肿瘤大小为 50mm 或更大(P=0.041)是多因素分析中的独立预后因素,且静脉接触和肿瘤大小均为 50mm 或更大的患者的总生存率与不可切除组相当(P=0.547)。
静脉受累程度可能与胰头癌的可切除性无关,而发生静脉侵犯且肿瘤大小为 50mm 或更大的肿瘤可能被归类为边界可切除的胰腺癌。